Drug Trial Radar · NCT01932242
Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
Last checked: Nov 20, 2026Latest source record: May 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Jul 23, 2013
Primary completion
Apr 19, 2014
Study completion Apr 19, 2014
Sponsor
- Lead sponsor
- Elusys TherapeuticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 30, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of repeat administration (two doses) of intravenous (IV) ETI-204.
Conditions
- Inhalational Anthrax
Interventions
ETI-204Biological
Monoclonal Antibody
PlaceboOther
Placebo for ETI-204
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Adverse EventsTime frame: Up to 191 days or 221 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each arm.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Quintiles
Overland Park, Kansas
DaVita
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.